Future studies should consider using more recent samples than those from the Look AHEAD, ACCORD, and VADT trials, as newer classes of medications have become available for managing T2DM (e.g., glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) [52], potentially impacting the relationship between HbA1c and CAD in the different Hp phenotype groups. This evidence concerns the gene HP and coronary artery disorder.